A Study to Evaluate the Safety and Immunogenicity of Quadrivalent Influenza Vaccine

Influenza Clinical Trial

Official title:

A Phase III, Prospective, Randomized, Open-Labeled, Active-Controlled, Multi-Center Study to Evaluate the Safety and Immunogenicity of Quadrivalent Influenza Vaccine, GC FLU, in Adults Aged 20 to 50

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03718468
• Other study ID #: CT-QV-31
• Status: Completed
• Phase: Phase 3
• Start date: October 30, 2018
• Est. completion date: July 3, 2019

Study information

• Verified date: August 2019
• Source: Medigen Vaccine Biologics Corp.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study aims to demonstrate the immunogenic efficacy of GC FLU Quadrivalent Pre-filled Syringe inj. (GC FLU), a quadrivalent influenza virus vaccine, is non-inferior to the active control, Fluarix Tetra. This study is designed to be a randomized, open-labelled, active-controlled, parallel, phase III study recruiting subjects from multiple study sites.

Approximately 840 eligible subjects are planned to enroll in order to obtain 800 evaluable (= per-protocol) subjects. Subjects will be randomized and assigned to GC FLU or Fluarix Tetra (active control, AC) group in 1:1 ratio.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 842
• Est. completion date: July 3, 2019
• Est. primary completion date: July 3, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 20 Years to 50 Years

Eligibility

Inclusion Criteria:

1. Provision of signed and dated informed consent form

2. Either gender, aged 20 to 50 years old (inclusive)

3. Willing and able to comply with all the required study visits and follow-up defined by this protocol

4. Female subject with childbearing potential or male subject with female spouse/partner with childbearing potential must agree to use highly effective contraceptives from 15 days prior to vaccination until 60 days after vaccination. At least two forms of birth control must be adopted and one of which must be a barrier method. Acceptable forms include:

• Established use of oral, injected or implanted hormonal methods of contraception

• Placement of an intrauterine device (IUD) or intrauterine system (IUS)

• Barrier methods of contraception: condom, or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository

Exclusion Criteria:

1. With previous known or potential exposure to influenza virus within 12 weeks prior to vaccination

2. Received seasonal influenza vaccine (registered or investigational) within 24 weeks prior to vaccination

3. Received any vaccine other than seasonal influenza vaccine within 6 weeks prior to vaccination

4. Received other investigational products (including medications and vaccines) within 6 weeks prior to vaccination

5. Administered immunoglobulins and/or other blood products within the 12 weeks prior to vaccination

6. Known or suspected hypersensitivity to any component of vaccines (including egg proteins); or history of allergy to consumption of eggs

7. History of inflammatory or degenerative neurological disease (e.g., Guillain-Barre syndrome)

8. With confirmed or suspected immunosuppressive or immunodeficient condition (e.g. HIV infection), or received > 14 days of systemic steroid with equivalent dosage equal or over to 0.5 mg/kg/day prednisolone or other immune-modifying agents within 24 weeks prior to vaccination

9. Positive in HIV, HBsAg, or HCV test

10. With fever (defined as body temperature equal or over to 38 °C by any method) on the day of vaccination

11. With ongoing acute diseases or within the past 2 years serious medical conditions (e.g. concomitant illness) such as cardiovascular (e.g. New York Heart Association grade III or IV), hepatic (e.g. Child-Pugh Class C), psychiatric condition (e.g. alcoholism, drug abuse), medical history, physical findings, or laboratory abnormality that in the investigators' opinion could interfere with the results of the trial or adversely affect the safety of the subject

12. Female subject who is lactating or has positive serum or urine pregnancy test at screening or vaccination

Related Conditions & MeSH terms

• Influenza
• Influenza, Human

Intervention

Biological:
• GC FLU Quadrivalent
A single dose administration of GC FLU Quadrivalent will be through intramuscular injection.
• Fluarix Tetra
A single dose administration of Fluarix Tetra will be through intramuscular injection.

Locations

Country	Name	City	State
Taiwan	National Taiwan University Hospital	Taipei
Taiwan	Taipei Municipal Wan Fang Hospital	Taipei
Taiwan	Tri-Service General Hospital	Taipei
Taiwan	Linkou Chang Gung Memorial Hospital	Taoyuan

Sponsors (1)

Lead Sponsor	Collaborator
Medigen Vaccine Biologics Corp.

Country where clinical trial is conducted

Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The Geometric Mean Titer (GMT) Ratio	The non-inferior immunogenicity of GC FLU compared to active control in terms of HAI titers against each virus strain at 21 days after the vaccination.	21 days after the vaccination
Primary	The Seroconversion Rate	The non-inferior immunogenicity of GC FLU compared to active control in terms of HAI titers against each virus strain at 21 days after the vaccination.	21 days after the vaccination